One More Score: CBO Projects HHS Rebate Proposal Would Boost Part D Spending $170bn
HHS downplays latest attempt to predict “complex behavior changes to a broken system.”
You may also be interested in...
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.
Medicare Price Negotiation, Inflation Rebate Legislation Would Generate $163Bn, CBO Says
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.
The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.